Sensius B.V., founded in 2015 and based in Rotterdam, Netherlands, specializes in innovative cancer treatment through deep thermotherapy specifically targeting the head and neck region. As an Erasmus MC spinoff, the company focuses on developing novel hyperthermia techniques to enhance cancer care, providing a promising approach to improve treatment outcomes for patients suffering from tumors in these areas.
TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, focused on developing genetically modified oncolytic viruses to improve cancer treatments. Established in 2013, the company aims to enhance tumor T-cell therapies through its patented technology, which utilizes oncolytic viruses to modify the tumor microenvironment and counteract its immune-suppressive properties. TILT Biotherapeutics is advancing several product candidates, including TILT-123, TILT-234, and TILT-321, and plans to translate its innovative approach into clinical trials. The technology is designed to bolster the effectiveness of tumor-infiltrating lymphocyte (TIL) therapies, chimeric antigen receptor (CAR-T) therapies, and checkpoint inhibitors, potentially achieving outcomes in solid tumors similar to those seen in hematological cancers.
TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, focused on developing genetically modified oncolytic viruses to improve cancer treatments. Established in 2013, the company aims to enhance tumor T-cell therapies through its patented technology, which utilizes oncolytic viruses to modify the tumor microenvironment and counteract its immune-suppressive properties. TILT Biotherapeutics is advancing several product candidates, including TILT-123, TILT-234, and TILT-321, and plans to translate its innovative approach into clinical trials. The technology is designed to bolster the effectiveness of tumor-infiltrating lymphocyte (TIL) therapies, chimeric antigen receptor (CAR-T) therapies, and checkpoint inhibitors, potentially achieving outcomes in solid tumors similar to those seen in hematological cancers.
ATXA Therapeutics Limited is a pharmaceutical company based in Dublin, Ireland, focused on developing novel small molecule drugs for the treatment of pulmonary arterial hypertension (PAH). Established in 2015 as a spin-out from University College Dublin, the company has leveraged over 20 years of research and more than €15 million in grant funding to advance its clinical trials and secure marketing authorization for its therapies. ATXA's innovative approach involves targeting human thromboxane receptors to enhance vasodilation and reduce vasoconstriction, addressing significant unmet medical needs in PAH and other cardiovascular conditions. The team comprises experts in various fields, including cardiovascular and cancer biology, drug discovery, and preclinical pharmacokinetics, positioning ATXA to develop more effective treatments than current standard care options. The company aims to improve treatment outcomes for patients suffering from PAH and related conditions through its advanced therapies.
CYTO365 is the manufacturer of RondelO multi inlet stopcock, which is sold as a component aimed to be integrated into IV-set to combat Drug Incompatibility due to parallel infusion.
Protinhi Therapeutics is a preclinical stage biotechnology company focused on developing antiviral drugs to combat various viral threats, including dengue, Zika, and COVID-19. The company's innovative approach utilizes proprietary technology and compounds that target viral diseases through protease inhibition. This mechanism disrupts the viruses' ability to replicate, providing healthcare providers with a means to effectively control the spread of these infections. By concentrating on significant public health challenges, Protinhi Therapeutics aims to contribute to global efforts in managing and mitigating viral outbreaks.
Selio is a simple, effective and patent protected technology. The Selio prototype has been rigorously tested in the lab and in subsequent acute pre-clinical in vivo studies with very positive results.
Restore Medical develops and provides a device-based therapy for congestive heart failure. It improves patient quality of life and reduce hospital readmission rates. Restore Medical's product, ContraBand, is a novel catheter-delivered implant in the pulmonary arteries for treatment of left ventricle failure, for patients with preserved right ventricle function. Restore Medical was founded in 2016 and is headquartered in Or Yehuda, Israel.
Ovagen is a biotechnology company that has developed the process of producing germ free (GF) chicken eggs and GF birds in commercial quantities for use primarily in the pharmaceutical industry. Ovagen can also provide a Contract Research Service and has extensive expertise in SPF poultry & rodent housing & husbandry, in specific poultry & rodent research technologies to GMP standards and in avian transgenics.
Synergia Medical SA, founded in 2013 and based in Mont-Saint-Guibert, Belgium, specializes in the development of innovative neurostimulation medical devices. The company is focused on creating optoelectronic neurostimulators that utilize advanced materials, optical components, biosensors, and microelectronics. In particular, Synergia Medical aims to manufacture MRI-safe, implanted devices designed for treating drug-resistant epilepsy, with potential applications in other therapeutic areas. The company has achieved ISO13485 certification within a short period and has successfully developed and marketed an OEM external neurostimulator for motorized amputee prostheses. Supported by private investors and public research grants, Synergia Medical has rapidly expanded its team to include thirteen skilled professionals dedicated to advancing neurostimulation technology.
Qubit Pharmaceuticals, incorporated in 2020 and based in Paris, France, develops innovative technology aimed at enhancing pharmaceutical drug discovery. The company offers a drug discovery simulation platform that reduces the cost and duration of preclinical drug development. Utilizing proprietary force field models and molecular dynamics calculations, Qubit's platform conducts virtual screening and visualization to identify promising drug candidates. This approach leverages quantum physics to support biopharmaceutical companies in accelerating their research and development efforts.
ATRO Medical B.V., based in Nijmegen, the Netherlands, specializes in the development of an anatomically shaped polymer-based meniscus implant known as the Trammpolin. This innovative implant is designed to restore the protective function of the meniscus by acting as a spacer in the joint. ATRO Medical emerged as a spin-out from DSM and Radboudumc, leveraging expertise gained from a collaborative initiative that began in 2010, which included universities, private companies, and support from the Dutch government. The company combines clinical, biomechanical, and polymer knowledge to advance the Trammpolin design and its prototype development.
Loci Orthopaedics Limited is a medical technology company based in Upper Newcastle, Ireland, focused on developing innovative solutions for orthopedic care. Established in 2017, the company specializes in the InDx implant, which is designed to treat arthritis in the thumb base joint. This implant uniquely mimics the natural motions of the thumb joint, providing a less invasive and easier insertion method compared to existing surgical options. Loci Orthopaedics also emphasizes evidence-based designs in its products, aiming to address significant unmet clinical needs in orthopedic extremities.
Loci Orthopaedics Limited is a medical technology company based in Upper Newcastle, Ireland, focused on developing innovative solutions for orthopedic care. Established in 2017, the company specializes in the InDx implant, which is designed to treat arthritis in the thumb base joint. This implant uniquely mimics the natural motions of the thumb joint, providing a less invasive and easier insertion method compared to existing surgical options. Loci Orthopaedics also emphasizes evidence-based designs in its products, aiming to address significant unmet clinical needs in orthopedic extremities.
Nuclidium’s vision is to address the unmet need to detect and stage cancer more accurately so that treatment options for cancer patients and their long-term survival can be significantly improved.
TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, focused on developing genetically modified oncolytic viruses to improve cancer treatments. Established in 2013, the company aims to enhance tumor T-cell therapies through its patented technology, which utilizes oncolytic viruses to modify the tumor microenvironment and counteract its immune-suppressive properties. TILT Biotherapeutics is advancing several product candidates, including TILT-123, TILT-234, and TILT-321, and plans to translate its innovative approach into clinical trials. The technology is designed to bolster the effectiveness of tumor-infiltrating lymphocyte (TIL) therapies, chimeric antigen receptor (CAR-T) therapies, and checkpoint inhibitors, potentially achieving outcomes in solid tumors similar to those seen in hematological cancers.
Venari Medical Limited, founded in 2018 and based in Galway, Ireland, develops innovative medical devices aimed at treating chronic venous diseases (CVD). The company's flagship product, BioVena, employs the body's natural healing processes to provide a more effective and less invasive treatment option for conditions such as varicose veins and venous ulcers. Venari Medical seeks to address the significant gap in treatment, as only a small fraction of the 120 million individuals suffering from venous disease in the US and EU receive adequate care. Their technology not only offers a safer alternative to existing methods but also targets the underserved population of venous ulcer patients who currently rely on ineffective compression bandaging. By widening the indications for superficial venous ablation, Venari Medical aims to reduce the annual costs associated with venous ulcers, which total approximately $33 billion for insurers in these regions. The company's commitment to patient-centered solutions positions it to disrupt traditional treatment practices that have seen limited innovation in recent years.
Perha Pharmaceuticals is a biotechnology company dedicated to the research and development of innovative therapies aimed at addressing hearing loss and cognitive disorders. The company focuses on preventing cisplatin-induced hearing loss and developing treatments for cognitive conditions related to Down syndrome and Alzheimer's disease. Perha Pharmaceuticals leverages natural marine substances in its research, with chemists and biologists optimizing molecules derived from marine organisms to create effective kinase inhibitors. This approach underscores the company's commitment to advancing medical treatments and improving patient care in areas of significant unmet need.
Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that serve as a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, focusing particularly on transcriptomics. By enabling single-cell barcoding in a test tube format, Scipio Bioscience's products facilitate advanced research in single-cell analysis, supporting laboratories in their scientific endeavors.
Ovagen is a biotechnology company that has developed the process of producing germ free (GF) chicken eggs and GF birds in commercial quantities for use primarily in the pharmaceutical industry. Ovagen can also provide a Contract Research Service and has extensive expertise in SPF poultry & rodent housing & husbandry, in specific poultry & rodent research technologies to GMP standards and in avian transgenics.
Genetika+ is developing a personalized medical testing tool to better treat depression by helping physicians find the best drug therapy for their patients. The Genetika+ test uses innovative technology to predict the best drug treatment for each patient, enabling faster treatment, fewer side effects, and lower dosing.
Nagi Bioscience SA, based in Lausanne, Switzerland, specializes in the development and manufacturing of an innovative automated testing device that utilizes Caenorhabditis elegans, a type of microscopic worm, for the assessment of substances in pharmaceutical, chemical, and cosmetic industries. This technology, known as "Organism-on-Chip," integrates in vivo testing with a fully automated in vitro platform for handling, culturing, and analyzing these organisms. Nagi Bioscience's solutions facilitate toxicity testing, drug discovery, and anthelmintic testing, allowing clients to gain insights into the complete biological responses that can only be observed at the organism level. This approach aims to transform traditional methods of evaluating the toxic or beneficial effects of various substances.
Betalin Therapeutics is a privately-held company focused on developing a cell therapy solution for insulin-dependent diabetes through its Engineered Micro-Pancreas (EMP) technology. The EMP combines harvested pancreatic islets, known as Islets of Langerhans, with a proprietary biological micro-environment designed to support these cells. After achieving promising in-vitro results and preliminary in-vivo outcomes, the company is working to further optimize its therapy in animal models. Betalin Therapeutics aims to complete the submission of its Investigational New Drug application to the FDA and advance to clinical trials, with the goal of providing an alternative to traditional insulin therapy and eliminating the need for insulin injections and glucose testing in diabetes patients.
Amadix is focused on developing and commercializing innovative cancer diagnostic technologies that address unmet medical needs in oncology. The company's flagship product, Colofast, is a non-invasive screening signature for colorectal cancer and advanced adenoma diagnosis, aimed at reducing the high mortality rate associated with colon cancer. Amadix's approach emphasizes early detection, allowing for timely treatment while avoiding the complications of invasive procedures like tumor biopsies. The team comprises industry veterans with extensive expertise in oncology diagnostics, the pharmaceutical industry, and biotechnology, supported by independent board members who provide strategic guidance in commercialization and business development, particularly in Europe and the United States. Amadix's products undergo rigorous analytical validation and clinical studies before being introduced to the global market.
VBL Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative treatments for cancer and immune-inflammatory diseases. Founded to address significant unmet medical needs, the company focuses on creating therapies that surpass the limitations of currently available options. Its clinical pipeline is built on two proprietary platform technologies that utilize the body’s natural physiological and genetic regulatory mechanisms. The lead candidate, VB-111, is a gene-based biologic targeting solid tumors, specifically for recurrent glioblastoma, an aggressive brain cancer. In addition to its oncology efforts, VBL is also advancing a program aimed at anti-inflammatory diseases, leveraging its Lecinoxoid platform technology.
VBL Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative treatments for cancer and immune-inflammatory diseases. Founded to address significant unmet medical needs, the company focuses on creating therapies that surpass the limitations of currently available options. Its clinical pipeline is built on two proprietary platform technologies that utilize the body’s natural physiological and genetic regulatory mechanisms. The lead candidate, VB-111, is a gene-based biologic targeting solid tumors, specifically for recurrent glioblastoma, an aggressive brain cancer. In addition to its oncology efforts, VBL is also advancing a program aimed at anti-inflammatory diseases, leveraging its Lecinoxoid platform technology.
Perha Pharmaceuticals is a biotechnology company dedicated to the research and development of innovative therapies aimed at addressing hearing loss and cognitive disorders. The company focuses on preventing cisplatin-induced hearing loss and developing treatments for cognitive conditions related to Down syndrome and Alzheimer's disease. Perha Pharmaceuticals leverages natural marine substances in its research, with chemists and biologists optimizing molecules derived from marine organisms to create effective kinase inhibitors. This approach underscores the company's commitment to advancing medical treatments and improving patient care in areas of significant unmet need.
Criam is a biotechnology company based in Braga, Portugal, founded in 2015, that focuses on developing medical devices for blood type analysis and disease detection. The company's flagship product, also named Criam, enables rapid and affordable blood test analysis, allowing users to receive immediate information about their health. This medical device can detect various diseases, including HIV, Brucella, tick fever, syphilis, mononucleosis, and meningitis. By positioning itself in the Point-of-Care diagnostic segment, Criam aims to empower individuals with timely health information and contribute to the global monitoring and control of diseases.
Colospan Ltd is a clinical-stage medical device company based in Kfar Saba, Israel, established in 2010. It specializes in developing innovative technology aimed at improving outcomes in colorectal surgeries. The company has created a proprietary, single-use intraluminal bypass device designed to minimize the risk of anastomotic leaks following intestinal surgery, particularly in patients with severe inflammatory bowel diseases or colorectal cancer. This device helps reduce contact between fecal matter and the anastomotic site, thereby decreasing the likelihood of complications that could lead to prolonged hospitalization or the need for additional surgeries. By offering a temporary alternative to diverting colostomies, Colospan's products aim to enhance patient recovery while maintaining overall well-being and safety during the post-operative period.
Palobiofarma S.L. is a biotechnology company based in Barcelona, Spain, with an additional facility in Navarra. Founded in 2005, the company specializes in the discovery and development of new drugs that target adenosine receptors, with a focus on treating advanced prostate cancer. By leveraging medicinal chemistry and in vitro pharmacology, Palobiofarma aims to be the first European company to market a selective adenosine receptor modulator, addressing significant medical needs through innovative therapeutic approaches.
Palobiofarma S.L. is a biotechnology company based in Barcelona, Spain, with an additional facility in Navarra. Founded in 2005, the company specializes in the discovery and development of new drugs that target adenosine receptors, with a focus on treating advanced prostate cancer. By leveraging medicinal chemistry and in vitro pharmacology, Palobiofarma aims to be the first European company to market a selective adenosine receptor modulator, addressing significant medical needs through innovative therapeutic approaches.
EpiEndo Pharmaceuticals is a privately held Icelandic pharmaceutical company developing a proprietary portfolio of compounds with epithelial barrier enhancing properties. EpiEndo is seed-funded, privately held and in preclinical development.EpiEndo is focusing on chronic respiratory diseases. First clinical trials are planned for the year 2019.EpiEndo is run as an international virtual organization coordinated by a team that consists of founding CEO Dr. Fridrik Runar Gardarsson and COO & CFO Birgir Magnusson, who coordinate a network of specialized service providers.
Positrigo AG develops and manufactures brain PET scanners. It offers solutions for providing functional brain positron emission tomography scans to the masses for the early detection of Alzheimer's disease. The company was founded in 2018 and is based in Zurich, Switzerland.
RemedyBio is an immunology-focused discovery and development company based in Dublin, Ireland. It has pioneered a new approach to understanding the immune system and the discovery of new therapies.
Xenothera SAS is a biotechnology company based in Nantes, France, focused on advancing immunological treatments through its innovative platform. Established in 2014, the company specializes in developing therapeutic solutions targeting various medical areas, including immunomodulation and infectious diseases. Its approach leverages proprietary Glyco-Humanized Antibodies and integrates expertise in animal genetics and immunology to create a new generation of hyperimmune polyclonal sera. By renovating passive immunotherapy, Xenothera aims to address unmet medical needs and facilitate the rapid development of new immunological therapies. The company's comprehensive platform allows for streamlined processes, from selecting immunogens to purifying immunoglobulins, ultimately aiming for expedited market authorization.
Xenothera SAS is a biotechnology company based in Nantes, France, focused on advancing immunological treatments through its innovative platform. Established in 2014, the company specializes in developing therapeutic solutions targeting various medical areas, including immunomodulation and infectious diseases. Its approach leverages proprietary Glyco-Humanized Antibodies and integrates expertise in animal genetics and immunology to create a new generation of hyperimmune polyclonal sera. By renovating passive immunotherapy, Xenothera aims to address unmet medical needs and facilitate the rapid development of new immunological therapies. The company's comprehensive platform allows for streamlined processes, from selecting immunogens to purifying immunoglobulins, ultimately aiming for expedited market authorization.
Sensius B.V., founded in 2015 and based in Rotterdam, Netherlands, specializes in innovative cancer treatment through deep thermotherapy specifically targeting the head and neck region. As an Erasmus MC spinoff, the company focuses on developing novel hyperthermia techniques to enhance cancer care, providing a promising approach to improve treatment outcomes for patients suffering from tumors in these areas.
Qubit Pharmaceuticals, incorporated in 2020 and based in Paris, France, develops innovative technology aimed at enhancing pharmaceutical drug discovery. The company offers a drug discovery simulation platform that reduces the cost and duration of preclinical drug development. Utilizing proprietary force field models and molecular dynamics calculations, Qubit's platform conducts virtual screening and visualization to identify promising drug candidates. This approach leverages quantum physics to support biopharmaceutical companies in accelerating their research and development efforts.
Sunrise aims to bring simple answers to millions of people suffering from sleep disorders. We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate as in-lab sleep studies, at a fraction of the cost. Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases. Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems.
MedTrace Pharma A/S is a medical device company based in Kongens Lyngby, Denmark, with additional offices in Boston, Massachusetts, and Uppsala, Sweden. Founded in 2015, the company specializes in the development of innovative solutions for positron emission tomography (PET) imaging. Its flagship product, the MT-100, is an automated system designed for on-site production and infusion of the tracer 15O-water, which enhances the sensitivity of PET scans and improves patient throughput. MedTrace also offers aQuant, an analytical platform that interprets the PET scan results, enabling physicians to obtain accurate blood flow measurements in various clinical applications, including heart studies and tumor vascularization. The integration of these technologies aims to revolutionize PET diagnostic imaging by providing safer and more efficient tools for healthcare professionals.
EpiEndo Pharmaceuticals is a privately held Icelandic pharmaceutical company developing a proprietary portfolio of compounds with epithelial barrier enhancing properties. EpiEndo is seed-funded, privately held and in preclinical development.EpiEndo is focusing on chronic respiratory diseases. First clinical trials are planned for the year 2019.EpiEndo is run as an international virtual organization coordinated by a team that consists of founding CEO Dr. Fridrik Runar Gardarsson and COO & CFO Birgir Magnusson, who coordinate a network of specialized service providers.
CarThera SAS specializes in the design and development of therapeutic ultrasound-based medical devices aimed at treating brain disorders. Founded in 2010 and headquartered in Paris, France, the company has developed innovative devices such as SonoProbe, which addresses conditions like brain tumors, epilepsy, metastases, and meningioma. Another key product is SonoCloud, an intracranial ultrasound implant that temporarily opens the blood-brain barrier, enhancing the delivery and concentration of therapeutic molecules for the treatment of primary brain tumors. Through these advancements, CarThera is focused on improving treatment outcomes for patients with serious neurological conditions.
CarThera SAS specializes in the design and development of therapeutic ultrasound-based medical devices aimed at treating brain disorders. Founded in 2010 and headquartered in Paris, France, the company has developed innovative devices such as SonoProbe, which addresses conditions like brain tumors, epilepsy, metastases, and meningioma. Another key product is SonoCloud, an intracranial ultrasound implant that temporarily opens the blood-brain barrier, enhancing the delivery and concentration of therapeutic molecules for the treatment of primary brain tumors. Through these advancements, CarThera is focused on improving treatment outcomes for patients with serious neurological conditions.
Positrigo AG develops and manufactures brain PET scanners. It offers solutions for providing functional brain positron emission tomography scans to the masses for the early detection of Alzheimer's disease. The company was founded in 2018 and is based in Zurich, Switzerland.
Osivax SAS is a clinical-stage biotechnology company based in Paris, France, founded in 2017. The company specializes in the development of innovative vaccines and immunotherapies aimed at addressing infectious diseases and enhancing immune responses. Its proprietary technology includes oligoDOM v1.0 and oligoDOM v2.0, which are designed to improve both B and T-cell immune responses by facilitating the uptake of antigens into dendritic cells. This results in more effective immune responses, including significant activation of CD8 T cells. Osivax's approach allows for the development of a universal vaccine targeting various infectious diseases, including influenza, malaria, and emerging coronavirus strains, while also showing potential applications in cancer treatment.
Osivax SAS is a clinical-stage biotechnology company based in Paris, France, founded in 2017. The company specializes in the development of innovative vaccines and immunotherapies aimed at addressing infectious diseases and enhancing immune responses. Its proprietary technology includes oligoDOM v1.0 and oligoDOM v2.0, which are designed to improve both B and T-cell immune responses by facilitating the uptake of antigens into dendritic cells. This results in more effective immune responses, including significant activation of CD8 T cells. Osivax's approach allows for the development of a universal vaccine targeting various infectious diseases, including influenza, malaria, and emerging coronavirus strains, while also showing potential applications in cancer treatment.
Osivax SAS is a clinical-stage biotechnology company based in Paris, France, founded in 2017. The company specializes in the development of innovative vaccines and immunotherapies aimed at addressing infectious diseases and enhancing immune responses. Its proprietary technology includes oligoDOM v1.0 and oligoDOM v2.0, which are designed to improve both B and T-cell immune responses by facilitating the uptake of antigens into dendritic cells. This results in more effective immune responses, including significant activation of CD8 T cells. Osivax's approach allows for the development of a universal vaccine targeting various infectious diseases, including influenza, malaria, and emerging coronavirus strains, while also showing potential applications in cancer treatment.
Resistell is a antibiotic resistance test.
Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy.
RemedyBio is an immunology-focused discovery and development company based in Dublin, Ireland. It has pioneered a new approach to understanding the immune system and the discovery of new therapies.
Ability Pharmaceuticals, S.L. is a clinical stage biopharmaceutical company based in Barcelona, Spain, dedicated to the discovery and development of human therapeutics for cancer and other unmet medical needs. The company specializes in creating Lipid Analogue Therapeutics, a novel class of small molecules designed to be administered orally. Its primary focus is on developing treatments for lung, pancreatic, and gynecological cancers. The development pipeline includes ABTL0812, which targets the Akt/mTOR signaling pathways, and ABTL0815, currently in preclinical characterization. Ability Pharmaceuticals develops its drug candidates up to clinical proof of concept before out-licensing them to pharmaceutical companies for further development. Founded in 2009, the company was formerly known as AB Therapeutics, S.L. and changed its name in September 2012.
Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy.
Xenothera SAS is a biotechnology company based in Nantes, France, focused on advancing immunological treatments through its innovative platform. Established in 2014, the company specializes in developing therapeutic solutions targeting various medical areas, including immunomodulation and infectious diseases. Its approach leverages proprietary Glyco-Humanized Antibodies and integrates expertise in animal genetics and immunology to create a new generation of hyperimmune polyclonal sera. By renovating passive immunotherapy, Xenothera aims to address unmet medical needs and facilitate the rapid development of new immunological therapies. The company's comprehensive platform allows for streamlined processes, from selecting immunogens to purifying immunoglobulins, ultimately aiming for expedited market authorization.
SOMAprobes S.L. develops healthcare technology for magnetic resonance imaging detection of bacterial pathogens at the onset of infectious disease. The company was incorporated in 2014 and is based in Donostia, Spain.
Betalin Therapeutics is a privately-held company focused on developing a cell therapy solution for insulin-dependent diabetes through its Engineered Micro-Pancreas (EMP) technology. The EMP combines harvested pancreatic islets, known as Islets of Langerhans, with a proprietary biological micro-environment designed to support these cells. After achieving promising in-vitro results and preliminary in-vivo outcomes, the company is working to further optimize its therapy in animal models. Betalin Therapeutics aims to complete the submission of its Investigational New Drug application to the FDA and advance to clinical trials, with the goal of providing an alternative to traditional insulin therapy and eliminating the need for insulin injections and glucose testing in diabetes patients.
MedTrace Pharma A/S is a medical device company based in Kongens Lyngby, Denmark, with additional offices in Boston, Massachusetts, and Uppsala, Sweden. Founded in 2015, the company specializes in the development of innovative solutions for positron emission tomography (PET) imaging. Its flagship product, the MT-100, is an automated system designed for on-site production and infusion of the tracer 15O-water, which enhances the sensitivity of PET scans and improves patient throughput. MedTrace also offers aQuant, an analytical platform that interprets the PET scan results, enabling physicians to obtain accurate blood flow measurements in various clinical applications, including heart studies and tumor vascularization. The integration of these technologies aims to revolutionize PET diagnostic imaging by providing safer and more efficient tools for healthcare professionals.
ADmit Therapeutics, S.L. is a biotechnology company based in Begues, Spain, dedicated to the development of diagnostic tests for the early detection of Alzheimer’s disease. Founded in 2017, the company utilizes epigenetic analysis of blood samples to identify a series of mitochondrial biomarkers that are not related to traditional indicators such as ß-amyloid or tau proteins. By analyzing a large number of methylcytosines in mitochondrial DNA through next-generation sequencing, ADmit Therapeutics provides a novel and accessible method for medical practitioners to detect early-stage Alzheimer’s disease. Their innovative approach primarily serves pharmaceutical companies, aiming to enhance diagnostic capabilities in the field of neurodegenerative diseases.
Ability Pharmaceuticals, S.L. is a clinical stage biopharmaceutical company based in Barcelona, Spain, dedicated to the discovery and development of human therapeutics for cancer and other unmet medical needs. The company specializes in creating Lipid Analogue Therapeutics, a novel class of small molecules designed to be administered orally. Its primary focus is on developing treatments for lung, pancreatic, and gynecological cancers. The development pipeline includes ABTL0812, which targets the Akt/mTOR signaling pathways, and ABTL0815, currently in preclinical characterization. Ability Pharmaceuticals develops its drug candidates up to clinical proof of concept before out-licensing them to pharmaceutical companies for further development. Founded in 2009, the company was formerly known as AB Therapeutics, S.L. and changed its name in September 2012.
EpiEndo Pharmaceuticals is a privately held Icelandic pharmaceutical company developing a proprietary portfolio of compounds with epithelial barrier enhancing properties. EpiEndo is seed-funded, privately held and in preclinical development.EpiEndo is focusing on chronic respiratory diseases. First clinical trials are planned for the year 2019.EpiEndo is run as an international virtual organization coordinated by a team that consists of founding CEO Dr. Fridrik Runar Gardarsson and COO & CFO Birgir Magnusson, who coordinate a network of specialized service providers.
EpiEndo Pharmaceuticals is a privately held Icelandic pharmaceutical company developing a proprietary portfolio of compounds with epithelial barrier enhancing properties. EpiEndo is seed-funded, privately held and in preclinical development.EpiEndo is focusing on chronic respiratory diseases. First clinical trials are planned for the year 2019.EpiEndo is run as an international virtual organization coordinated by a team that consists of founding CEO Dr. Fridrik Runar Gardarsson and COO & CFO Birgir Magnusson, who coordinate a network of specialized service providers.
Trisol Medical Ltd is a company based in Yokneam, Israel, that specializes in the development of transcatheter tricuspid replacement valves. Established in 2016, it focuses on innovative solutions in the field of cardiac interventions, specifically targeting the treatment of tricuspid valve diseases. As a portfolio company, Trisol Medical is positioned within the medical technology sector, aiming to enhance patient outcomes through its advanced valve replacement technologies.
Trisol Medical Ltd is a company based in Yokneam, Israel, that specializes in the development of transcatheter tricuspid replacement valves. Established in 2016, it focuses on innovative solutions in the field of cardiac interventions, specifically targeting the treatment of tricuspid valve diseases. As a portfolio company, Trisol Medical is positioned within the medical technology sector, aiming to enhance patient outcomes through its advanced valve replacement technologies.
Medicortex Finland is focused on developing a non-invasive, point-of-care diagnostic test for Traumatic Brain Injury (TBI) and concussions. Traditional diagnostic methods, such as CT and MRI scans, struggle to accurately diagnose mild TBIs. To address this, Medicortex is identifying brain injury biomarkers that can be detected from urine and saliva, with plans to incorporate these biomarkers into a hand-held diagnostic kit that provides rapid and reliable results without the need for medical professionals' interpretation. The company aims to collaborate with larger diagnostic firms for manufacturing and distribution. Its target customers include hospitals, emergency rooms, paramedics, military personnel, sports teams, pharmaceutical companies, and insurance providers. Medicortex has achieved significant milestones, including reaching Phase II clinical studies for its biomarker and receiving grant funding from the US Department of Defense, the European Union, and the Finnish Government.
Desentum Oy is a biopharmaceutical company based in Finland that focuses on developing innovative hypoallergenic vaccines aimed at treating various allergies, including those caused by pollen, pets, and certain food proteins. Established in 2011, Desentum employs a unique approach to allergy immunotherapy by altering the immune system's response to allergens, promoting tolerance instead of hypersensitivity. The company leverages its research into the molecular mechanisms behind allergic reactions to design effective vaccines that aim to provide long-term relief for patients suffering from allergic symptoms. By utilizing recombinant allergens modified to suppress histamine release during treatment, Desentum seeks to minimize adverse effects and streamline the desensitization process, ultimately addressing the social and economic burdens associated with allergies.